Skip Navigation
Print This Page
Share this page: More

Dr. John Isaacs

John Isaacs

Molecular Biology of Prostate Cancer


Professor of Oncology, JHU- School of Medicine

Professor of Urology, JHU-School of Medicine

Professor in the Cellular and Molecular Medicine Graduate Program, JHU-School of Medicine

Professor in Laboratory Training Program in Radiation Oncology and Molecular Radiation Sciences, JHU-School of Medicine

Professor in Anti-Cancer Drug Development Graduate Training Program, Department of Pharmacology and Molecular Science, JHU-School of Medicine

Professor in Chemical and Molecular Bioengineering, JHU- The Whiting School of Engineering

Member of Urological Oncology Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Member of Chemical Therapeautics Program, The Sidney Kimmel Comprehensive Cancer Center

Editor-in-Chief, The Prostate


Ph.D., Emory University, Atlanta, GA


Postdoctoral Fellow, Johns Hopkins School of Medicine

Clinical Interests

Prostate cancer

Clinical Research

drug development specifically in prostate cancer

Research Summary

Molecular biology of prostate cancer, drug development in paraticular prostate cancer

Journal Citations

Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007; 99:376-85.
Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT.
Amino acid containing thapsigargin analogues deplete androgen receptor protein via
synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009;
Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-
215050), a quinoline-3-carboxamide anti-angiogenic agent, modules the expression of
thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9:107.
Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-
generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate
cancer. Expert Opin Investig Drugs 2010; 19: 1235-43.
Dalrymple SL, Becker RE, Zhou H, DeWeese TL, and Isaacs JT. Tasquinimod Prevents the
Angiogenic Rebound Induced by Fractionated Radiation Resulting in an Enhanced
Therapeutic Response of Prostate Cancer Xenografts. Prostate 2012; 72: 638-48.
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-
expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol
Cancer Ther 2012; 11:257-66.
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B,
DeMarzo AM, Wilding G,Carducci MA, Dionne CA, Moller JV, Nissen P, Christensen
SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor
endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4:140ra86.
Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma associated
fibroblasts within the tumor stroma with a fibroblast activation protein (FAP)- activated
prodrug. JNCI 2012; 104 (September/ in press).
Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade
SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale
for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate.
2012 [Epub ahead of print]
Denmeade SR, Isaacs JT. Engineering Enzymatically Activated "Molecular Grenades" for
Cancer. Oncotarget 2012; (July 22/in press).


Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer